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Abstract
Several lines of evidence indicate that the use of stimulant drugs, including methylphenidate (MPD), increases tobacco smok-
ing. This has raised concerns that MPD use during adolescence could facilitate nicotine abuse. Preclinical studies have shown 
that repeated treatment with an addictive drug produces sensitization to that drug and usually cross-sensitization to other 
drugs. Behavioral sensitization has been implicated in the development of drug addiction. We examined whether repeated oral 
MPD administration during adolescence could induce behavioral sensitization to MPD and long-lasting cross-sensitization to 
nicotine. Adolescent male Wistar rats were treated orally with 10 mg/kg MPD or saline (SAL) from postnatal day (PND) 27 to 
33. To evaluate behavioral sensitization to MPD in adolescent rats (PND 39), the SAL pretreated group was subdivided into 
two groups that received intragastric SAL (1.0 mL/kg) or MPD (10 mg/kg); MPD pretreated rats received MPD (10 mg/kg). 
Cross-sensitization was evaluated on PND 39 or PND 70 (adulthood). To this end, SAL- and MPD-pretreated groups received 
subcutaneous injections of SAL (1.0 mL/kg) or nicotine (0.4 mg/kg). All groups had 8 animals. Immediately after injections, 
locomotor activity was determined. The locomotor response to MPD challenge of MPD-pretreated rats was not significantly 
different from that of the SAL-pretreated group. Moreover, the locomotor response of MPD-pretreated rats to nicotine challenge 
was not significantly different from that of the SAL-pretreated group. This lack of sensitization and cross-sensitization suggests 
that MPD treatment during adolescence does not induce short- or long-term neuroadaptation in rats that could increase sen-
sitivity to MPD or nicotine.
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Attention deficit hyperactivity disorder (ADHD) is the 
most commonly diagnosed and treated psychiatric disorder 
of childhood. The psychostimulant methylphenidate (MPD), 
commonly known as Ritalin®, is one of the most prescribed 
drugs for the treatment of ADHD. Children with ADHD are 
treated for several years, with drug administration often 
extending to adolescence and adulthood (1). MPD promotes 
many of the neurochemical effects typically associated with 
other psychomotor stimulants, including increases in extra-
cellular dopamine and norepinephrine (2). These effects are 
mediated by MPD binding to the dopamine transporter and 
to the norepinephrine transporter, respectively, which blocks 
the neurotransmitters’ transport through the nerve terminals 
(2). MPD may also act on serotonin transporters (3). 
Adolescence is characterized by increases in novelty 
seeking and risk taking behaviors, which could predispose 
to drug abuse initiation (4). Exposure to psychostimulants 
during adolescence can have long-term consequences 
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because early drug exposure may cause enduring adapta-
tions, which render the organism more susceptible to drug 
abuse and relapse later in life (5,6). 
Converging lines of evidence indicate that the use of 
stimulant drugs, including MPD, increases tobacco smoking in 
the natural environment and under controlled laboratory con-
ditions (7,8). This has raised concerns that MPD use during 
adolescence could induce long-term changes that facilitate 
nicotine abuse. Indeed, preclinical studies also suggest that 
MPD may enhance the abuse-related effects of nicotine, 
which could be linked to increased vulnerability to tobacco 
smoking. This suggestion emerges from results showing that 
acute MPD increased the rate of nicotine self-administration 
and dose dependently enhanced the discriminative stimulus 
effect of a low nicotine dose in rats (9). 
The mechanism underlying stimulant-induced increases 
in cigarette smoking is not clear; evidence from pre-clinical 
research suggests that the mesolimbic dopamine system 
may be the common pathway for this interaction. In fact, 
both psychostimulants and nicotine increase dopamine 
concentration in the nucleus accumbens (10,11). Moreover, 
repeated exposure to nicotine has been shown to induce 
changes in the dopamine mesolimbic system that might 
be similar to those produced by psychostimulant drugs. 
For example, enhanced accumbal dopamine output (12) 
and increased locomotor response to the dopamine D1/D2 
receptor agonist apomorphine have been reported following 
repeated exposure to nicotine (13). Repeated treatment 
with psychostimulants can induce behavioral sensitiza-
tion as evidenced by an enhanced locomotor response 
to a subsequent injection of the drug (14,15). Behavioral 
sensitization has been suggested as an animal model of 
neuroplasticity mainly associated with repeated administra-
tion of psychostimulant drugs and has been implicated in 
the development of drug addiction (14) and drug-induced 
psychosis (15). Repeated exposure to amphetamine, 
cocaine, fencamfamine, and methamphetamine has been 
shown to elicit behavioral sensitization (15-17). However, 
data of behavioral sensitization following repeated exposure 
to MPD have been contradictory, with reports of sensitiza-
tion (18-21) and no sensitization (22).
It has been known that repeated treatment with an 
addictive drug produces sensitization to that drug and 
cross-sensitization to other drugs of abuse (6,23). For ex-
ample, it has been demonstrated that repeated exposure 
to nicotine sensitizes the locomotor response to cocaine 
and amphetamine in periadolescent rats (24,25). It has also 
been demonstrated that long-term amphetamine (6,26) or 
caffeine (26) induces behavioral sensitization to nicotine. 
However, at present the degree to which repeated MPD 
treatment during adolescence subsequently augments the 
locomotor response to nicotine is still unclear. 
Although patients are treated with MPD orally, in most 
animal studies on MPD-induced behavioral effects, this 
drug was administered iv, ip, or sc. Evidence indicates that 
the behavioral effects of MPD significantly depend on the 
route of administration (22).
The aim of the present study was to examine whether 
repeated oral administration of MPD during adolescence 
could induce long-lasting behavioral sensitization to MPD 
and cross-sensitization to nicotine. For this purpose, rats 
were treated orally with 10 mg/kg of MPD from postnatal 
day (PND) 27 to 33 and locomotor activity was measured 
following a challenge injection of nicotine (0.4 mg/kg, sc) 
on PND 39 and PND 70. 
Material and Methods
Animals 
Male periadolescent Wistar rats (PND 27) as defined 
by Spear (4) from the animal breeding facility of the São 
Paulo State University were used. Groups of 4 animals were 
housed in plastic cages measuring 32 (width) x 40 (length) 
x 16 (height) cm in a room maintained at 21-23°C. Rats 
were kept on a 12/12-h light/dark cycle (lights on at 7:00 
am) and were allowed free access to food and water. All 
experiments were performed during the light phase. Control 
and experimental animals were randomly tested between 
8:00 am and 5:00 pm. Periadolescent male rats were at 
PND 27 and weighed an average of 130 g at the beginning 
of the experiment. Testing of different experimental groups 
was counterbalanced across time, i.e., animals from differ-
ent groups were evaluated on each test day.
The experimental protocol was approved by the Eth-
ics Committee for use of Human or Animal Subjects of the 
School of Pharmaceutical Science - UNESP (CEP-34/2005) 
and was conducted according to the principles of the Brazil-
ian College of Animals Experimentation (COBEA). 
Behavioral testing 
Behavioral testing was conducted in commercially 
available Plexiglas activity monitoring chambers (Colum-
bus Instruments, USA). The chambers, measuring 42 x 42 
cm, included 10 pairs of photocells, which were used to 
measure the horizontal locomotor activity. The consecutive 
interruption of two beams was registered as one locomo-
tion unit. The animals were allowed a 20-min adaptation 
period in the photocell apparatus before the injections and 
their locomotor activity was recorded immediately after the 
injections. Locomotion counts accumulated within 5-min 
intervals were recorded during a 15-min or 45-min testing 
session following nicotine or methylphenidate injections, 
respectively. The test session duration was based on the 
fact that previous experiments from our laboratory showed 
that the locomotor effects of 0.4 mg/kg (sc) nicotine and 10 
mg/kg (po) methylphenidate were more prominent at these 
times (data not shown). 
Pretreatment
Periadolescent rats were randomly divided into two 
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groups that received 10 mg/kg methylphenidate hydro-
chloride (MPD; Ritalin®, Novartis, Brazil) or saline (SAL) 
by gavage. Both groups were treated once daily for 7 
days (PND 27-33). Ritalin® was dissolved in saline and 
the dose was calculated based on the molecular weight 
of the MPD salt.
Behavioral sensitization to methylphenidate in 
adolescent rats
From day 8 to day 12 the animals did not receive any 
treatment. On day 13 (PND 39; 6 days after the last injection 
in the pretreatment phase) the group pretreated with saline 
was subdivided into two groups that received SAL (1.0 mL/
kg, po) or MPD (10 mg/kg, po). The group pretreated with 
MPD received a challenge dose of MPD (10 mg/kg, po). 
Thus, the following groups were studied: SAL + SAL (N = 8), 
SAL + MPD (N = 8), and MPD + MPD (N = 8). Immediately 
after the oral administrations their locomotor activity was 
recorded as described above. 
Cross-sensitization
Adolescent rats were pretreated with MPD or SAL 
as described above. After the last injection (on PND 33) 
the animals did not receive any treatment for 6 days. On 
PND 39, both SAL- and MPD-pretreated groups received 
a challenge dose of nicotine (NIC) (0.4 mg/kg, sc) or SAL 
(1.0 mL/kg, sc). 
A subset of adolescent rats received the same pretreat-
ment as described above and remained in the plastic cages 
without any treatment for 35 days. On PND 70 (adulthood), 
both SAL- and MPD-pretreated groups received a challenge 
dose of NIC (0.4 mg/kg, sc) or SAL (1.0 mL/kg, sc). 
The groups of adolescent and adult rats studied on the 
test day were: SAL + SAL (N = 8), SAL + NIC (N = 8) and 
MPD + NIC (N = 8). Immediately after the nicotine injections 
locomotor activity was determined as described above. 
Statistical analysis 
Data are reported as means ± SEM. Locomotor activ-
ity for each age was analyzed by one-way ANOVA. When 
ANOVA showed statistical significance, further analyses 
were performed by the Newman-Keuls test.
Results
Behavioral sensitization of adolescent rats to 
methylphenidate 
ANOVA showed significant differences in locomotor 
activity across groups [F(2,21) = 4.3; P < 0.05] of adolescent 
rats (Figure 1). Pairwise comparisons indicated that the 
behavioral response to MPD was higher in saline- (SAL + 
MPD) and MPD- (MPD + MPD) pretreated groups compared 
to the SAL + SAL group. The behavioral response to MPD 
challenge of MPD-pretreated rats was not significantly dif-
ferent from that of the SAL-pretreated group, indicating the 
lack of behavioral sensitization. 
Cross-sensitization 
ANOVA showed significant differences in locomotor 
Figure 1. Methylphenidate (MPD)-induced locomotor activity in 
adolescent rats. Animals were pretreated with saline (SAL) or 
MPD (10 mg/kg, po) for 7 days from postnatal day (PND) 27 to 
33. Six days after the last oral administration (PND 39), the ani-
mals received saline or MPD (10 mg/kg, po). The data are cumu-
lative locomotion counts during 45-min periods after oral adminis-
tration. Bars indicate the mean ± SEM for 8 animals per group. *P 
< 0.05 compared to the SAL-SAL group (Newman-Keul test).
Figure 2. Nicotine-induced locomotor activity in adolescent (A) 
or adult (B) rats. Animals were pretreated with saline (SAL) or 
methylphenidate (MPD) (10 mg/kg, po) for 7 days from postnatal 
day (PND) 27 to 33. Six (PND 39) or 36 (PND 70) days after the 
last MPD administration, animals received SAL or nicotine (NIC, 
0.4 mg/kg, sc). The data are cumulative locomotion counts during 
15-min periods after injection. Bars indicate the mean ± SEM for 
8 animals per group. *P < 0.01 compared to the SAL-SAL group 
(Newman-Keuls test).
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activity across groups of adolescent [F(2,21) = 8.67; P < 
0.01] and adult rats [F(2,19) = 4.52; P < 0.05; Figure 2A 
and B, respectively]. 
Comparisons across groups indicated for both adoles-
cent and adult rats that nicotine significantly increased loco-
motor activity in both saline- (SAL + NIC) and MPD- (MPD 
+ NIC) pretreated groups compared to the control (SAL + 
SAL) group. The behavioral response of MPD-pretreated 
rats to NIC challenge was not significantly different from 
that of the SAL-pretreated group (MPD + NIC vs SAL + 
NIC), indicating the lack of cross-sensitization.
Discussion
Our data demonstrated that repeated treatment with 
intragastric MPD did not induce behavioral sensitization 
in adolescent rats. Moreover, we did not observe cross-
sensitization between MPD and nicotine when the animals 
were challenged during adolescence or adulthood.
Several reports have demonstrated that repeated 
administration of MPD induces locomotor sensitization in 
adult animals (18,21,27). In addition, Torres-Reveron and 
Dow-Edwards (19) reported that repeated ip administra-
tion of MPD produced behavioral sensitization in adult and 
adolescent rats. 
In the present study, we found that repeated oral MPD 
administration during adolescence did not produce behav-
ioral sensitization when the challenge injection of MPD was 
administered during the same age period (PND 39). This 
finding agrees with previous results showing that recurrent 
administration of MPD did not elicit behavioral sensitization 
in adolescent animals (22,28). 
A possible explanation for these inconsistent findings 
concerns methodological variations. Specifically, factors 
such as dose, time and route of administration, as well as the 
motor indices recorded, can critically affect the observation 
of behavioral sensitization. For example, studies on cocaine 
sensitization in developing animals have also yielded con-
flicting results depending upon the age tested, the drug dos-
age, the intervals between the repetitive drug treatment, and 
the challenge dose (29,30). It has been shown that young 
animals chronically treated with stimulants rarely exhibit 
sensitization and, when sensitization occurs, it persists for 
a short period of time (31). The differences in circadian time 
of administration could also be one of the reasons for the 
inconsistent findings among several published reports. In 
a study in which MPD was injected at different times, only 
rats that were injected during the daytime between 8:00 
am and 14:00 pm exhibited behavioral sensitization (27). 
In the present study, we cannot rule out the possibility that 
repeated intragastric administration was a stressful condi-
tion that could sensitize the animals to MPD, as previously 
shown for other drugs and stress conditions (32,33). This 
could mask the observation of behavioral sensitization 
induced by repeated treatment with MPD. 
Cross-sensitization between drugs of abuse is sug-
gested to be one of the most reproducible paradigms to study 
whether exposure to the drug could increase vulnerability 
to the abuse of other substances. We investigated whether 
repeated treatment with oral MPD during adolescence could 
sensitize the animals to the locomotor effects of nicotine 
when the latter was administered during adolescence or 
adulthood. Our results showed a lack of cross-sensitization 
between MPD and nicotine at both ages tested. 
Several studies have reported that repeated treatment 
with MPD during adolescence caused cross-sensitization 
to cocaine and amphetamine (19,20,34). However, recently 
Guerriero et al. (28) showed that repeated MPD treatment 
of adolescent mice had no effect on locomotor sensitization 
to cocaine during adolescence or adulthood, suggesting 
that MPD treatment during adolescence does not induce 
long-term adaptations. 
It has been shown that pre-exposure to nicotine en-
hances the subsequent locomotor stimulant effect of acute 
psychostimulants such as cocaine and amphetamine 
(24,25). Nicotine-induced cocaine sensitization was ob-
served in male and female periadolescent rats (24) while 
cross-sensitization between nicotine and amphetamine was 
observed only in male periadolescent rats (25). Pretreatment 
with nicotine did not sensitize male or female adult rats to a 
subsequent psychostimulant injection in either study.
Recently, Wooters et al. (9) examined in adult rats 
the effect of repeated nicotine exposure on subsequent 
MPD-induced hyperactivity. They showed that nicotine 
pretreatment (0.2, 0.4, 0.6, or 0.8 mg/kg for 10 days) did 
not modify MPD-induced locomotor activity in response to 
the first injection administered 15 days after the last nicotine 
injection. This result suggests the lack of cross-sensitization 
between nicotine and MPD. However, Wooters et al. (9) 
observed that MPD sensitization emerged following the 
third injection of this drug in rats pretreated with the high-
est dose of nicotine. 
To our knowledge, the present study is the first to 
examine the effects of MPD pretreatment on nicotine-
induced locomotor activity. The result obtained is similar 
to that reported by Wooters et al. (9), showing the lack of 
cross-sensitization between nicotine and the first injection 
of MPD. In addition, based on Wooter’s (9) results showing 
cross-sensitization between nicotine and MPD following 
repeated administration, we cannot exclude the possibility 
that pretreatment with MPD could alter nicotine-induced 
locomotor activity if nicotine was repeatedly injected.
The lack of cross-sensitization suggests that MPD treat-
ment during adolescence does not induce short- or long-
term neuroadaptations. Although the present study did not 
address the neuropharmacological mechanisms underlying 
the interactive effects of MPD and nicotine, this is an impor-
tant subject for further research, particularly regarding the 
differences between the short- and long-term neuroadapta-
tions induced by MPD and other psychostimulants in ado-
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lescent and adult animals. Although MPD promotes many 
of the neurochemical effects typically associated with other 
psychomotor stimulants, including increases in extracellular 
dopamine and norepinephrine (2,3), there is evidence that 
the neuroadaptations induced by repeated MPD are differ-
ent from those observed with other psychostimulants. In 
this regard, it has been found that the transcription factor 
“cAMP response element binding” (CREB) was persistently 
up-regulated in the nucleus accumbens following recurrent 
MPD treatment of periadolescent (PND 20-35) rats (35). Of 
note, total CREB protein was unchanged following recurrent 
cocaine administration in adult rats (36). 
The present results also indicate the relevance of 
comparing adaptations following MPD administration by 
different routes. For instance, it has been shown that oral 
application of MPD to rodents increased extracellular 
norepinephrine in the hippocampus without significantly 
changing dopamine in the nucleus accumbens, which is 
essential for psychostimulants to induce behavioral sensi-
tization (22). Gerasimov et al. (37) compared the effects of 
intraperitoneal and oral MPD administration on dopamine 
levels and locomotor activity and showed that ip MPD was 
approximately twice as potent as oral MPD both in increasing 
extracellular dopamine levels and in stimulating locomotor 
activity at doses of 5 and 10 mg/kg. This was consistent 
with significantly higher plasma levels and brain uptake of 
3H-MPD observed after ip versus intragastric administration. 
The ability to reach peak levels within a short time is one of 
the main factors associated with the reinforcing properties 
and behavioral sensitization of MPD (38,39). Therefore, oral 
MPD is infrequently reported as being abused (40). Drug 
abusers, in order to obtain its reward effects, habitually use 
systemic routes of MPD administration (38,40). 
Our findings showed that oral MPD exposure during 
adolescence does not result in behavioral sensitization to 
the locomotor effect of nicotine either in adolescent or adult 
rats. Further investigations on the interaction between MPD 
and nicotine may provide relevant information to understand 
the interplay between MPD use and tobacco smoking.
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